X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XTMAB-16, an anti-TNFα monoclonal antibody which is being tested in a Phase 1b/2a clinical trial for its ability to potentially help patients with pulmonary sarcoidosis, a chronic, multisystem inflammatory disorder.
Lead Product(s): XTMAB-16
Therapeutic Area: Immunology Product Name: XTMAB-16
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
Under the agreement, Meitheal gains exclusive rights to commercialize XTMAB-16, a monoclonal antibody which aims to treat people with sarcoidosis, in North America and Xentria remains responsible for clinical development and retains the marketing rights in all other countries.
Lead Product(s): XTMAB-16
Therapeutic Area: Immunology Product Name: XTMAB-16
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Meitheal Pharmaceuticals
Deal Size: $680.0 million Upfront Cash: $45.0 million
Deal Type: Licensing Agreement June 27, 2023
Details:
XTMAB16, an Investigational new drug candidate, is a chimeric human-murine IgG1 anti-TNF monoclonal antibody being developed as a novel biologic product for treatment of sarcoidosis also, suppress the physiologic response to tumor necrosis factor.
Lead Product(s): XTMAB-16
Therapeutic Area: Rare Diseases and Disorders Product Name: XTMAB-16
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
